CTVA — Corteva, Inc.

Corteva Agriscience Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Q4 2025 Performance: Organic sales decreased by 4% year-over-year, with Crop Protection volumes down 2% and prices down 1%. Seed pricing increased by 3%, but volumes fell by 8%, largely due to timing shifts.
• Operating EBITDA: For Q4, operating EBITDA was down compared to the prior year, primarily due to lower volumes and higher compensation expenses, yet it marked the second-highest Q4 results since going public.
• Full Year Results: Organic sales increased by 4%, with operating EBITDA up 14% to $3.85 billion and margins expanding to over 22%. Free cash flow improved to $2.9 billion, up $1.2 billion from the previous year.
• 2026 Guidance: Operating EBITDA is projected to be between $4 billion and $4.2 billion, reflecting a 7% increase year-over-year. Operating EPS is expected to range from $3.45 to $3.70 per share.

2. Strategic Updates and Business Highlights

• Separation Update: Corteva is on track for a separation in the second half of 2026, with a new CEO search underway and plans to launch a new brand identity for SpinCo.
• Bayer Agreement: A comprehensive resolution with Bayer enhances Corteva's licensing capabilities, allowing for accelerated introductions of proprietary technologies and expected royalty neutrality by 2026—two years ahead of prior estimates.
• Seed Business Performance: The Seed segment saw organic growth across all regions, with significant cost improvements and share gains in corn and soybeans. The company anticipates a doubling of market share for Conkesta soybeans in Brazil in 2026.
• Crop Protection Business: Despite challenging market conditions, the Crop Protection segment achieved growth and margin expansion, with a strong pipeline of differentiated technologies.

3. Forward Guidance and Outlook

• 2026 Expectations: The company expects modest growth in the Crop Protection market, with volume growth driven by new products and biologicals. Pricing pressures are anticipated, particularly in Latin America.
• Cost Improvements: Corteva aims for $200 million in productivity savings in 2026, with a focus on maintaining operational efficiency and managing costs effectively.
• Market Dynamics: The company is preparing for potential shifts in crop acreage in the U.S. and anticipates stable demand for its differentiated products.

4. Bad News, Challenges, or Points of Concern

• Q4 Declines: The decrease in organic sales and operating EBITDA in Q4 raises concerns about volume performance and pricing pressures, particularly in Crop Protection.
• Competitive Pricing Pressures: Ongoing competitive pricing dynamics in Latin America and Asia Pacific are expected to impact margins, with specific concerns about pricing declines in the Crop Protection sector.
• Farmer Financial Stress: High interest rates and tight cash flows are stressing farmers in Latin America, which could affect purchasing behavior and demand for Corteva's products.

5. Notable Q&A Insights

• Bayer Agreement Clarifications: The agreement with Bayer allows Corteva to enter new markets and accelerate its licensing business, with significant financial upside projected over the next decade.
• Gene Editing Developments: There is optimism about the regulatory landscape for gene editing in Europe, which could open new markets for Corteva's products.
• Order Book Strength: The U.S. order book for Seed is strong, with prepay collections on par with prior years, although there may be shifts in crop planting patterns.
• Productivity and Cost Management: Corteva remains focused on productivity improvements, with a balanced approach to managing costs while navigating market challenges.

Overall, Corteva's Q4 2025 results reflect a strong year with significant growth in operating EBITDA and free cash flow, despite facing challenges in organic sales and pricing pressures. The company is strategically positioned for future growth with its separation plans and enhanced licensing capabilities.